Clinical Trial Update: High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study [Phase 2]

View source ↗

Summary

Phase 2 trial update for high-dose immunosuppression and autologous transplantation in relapsing-remitting multiple sclerosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2017-04-04